[ad_1]
The Competition Board imposed an administrative fine of TL 165.5 million on Novartis Sağlık and TL 113.0 million on Roche Müstahzarları. Novartis Health Food and Agricultural Products Industry. go Tic. AS. and Roche Müstahzarları San. The investigation was completed to determine if Law No. 4054 violated Article 4, in order to popularize the use of Lucentis, which is more expensive than the Altuzan and Lucentis drugs used in eye diseases.
According to the statement made by the Competition Board, as a result of the discussion of the file by the Competition Board on 21.01.2021, Novartis Sağlık Gıda ve Tarım Ürünleri San. go Tic. AS. and Roche Müstahzarları San. For violation of article 4 of Law No. 4054 by A.Ş., it was decided to impose an administrative fine on the aforementioned companies in accordance with article 16 of the same Law.
The statement read:
1) Novartis Sağlık Gıda ve Tarım Ürünleri San. go Tic. AS. and Roche Müstahzarları San. A.Ş. is in violation of Article 4 of Law No. 4054 UNANIMOUSLY.
2) Therefore, the third paragraph of article 16 of Law No. 4054 and the “Agreement Restricting Competition, Actions and Concerted Decisions and
In accordance with the provisions of subparagraph (a) of the first paragraph of Article 5 and subparagraph (b) of the second paragraph and third paragraph of the Regulation on fines to be imposed in case of abuse
– Novartis Health Food and Agricultural Products Industry. go Tic. A.Ş., 165,464,716.48 TL,
– Roche Müstahzarları San. A.Ş., with an administrative fine of 112,972,552.65 TL, has been decided unanimously, within 60 days after the notification of the reasoned decision, with a legal appeal in the Administrative Courts of Ankara.
